使用放射性标记的生长抑素类似物对髓样和非髓样甲状腺癌进行肽受体放射性核素治疗（PRRT）。

Peptide Receptor Radionuclide Therapy (PRRT) of Medullary and Nonmedullary Thyroid Cancer Using Radiolabeled Somatostatin Analogues.

作者信息

Salavati Ali, Puranik Ameya, Kulkarni Harshad R, Budiawan Hendra, Baum Richard P

机构信息

Department of Radiology, University of Pennsylvania, Philadelphia, PA; Department of Radiology, University of Minnesota, Minneapolis, MN.

Department of Nuclear Medicine, Bombay Hospital and MRC, Mumbai, India.

出版信息

Semin Nucl Med. 2016 May;46(3):215-24. doi: 10.1053/j.semnuclmed.2016.01.010.

DOI:10.1053/j.semnuclmed.2016.01.010

PMID:27067502

Abstract

As therapeutic options in advanced medullary and non-iodine avid differentiated (nonmedullary) thyroid cancers are limited and associated with significant toxicity, targeting of somatostatin receptors (SSTRs) for internal radiation therapy provides a promising option. Theranostics (therapy and diagnosis) using radiolabeled somatostatin analogues has proved to be a milestone in the management of SSTR-expressing tumors. Peptide receptor radionuclide therapy using (177)Lu-labeled or (90)Y-labeled somatostatin analogues may have a significant role in the management of medullary and nonmedullary thyroid cancers in those patients where PET/CT with (68)Ga-labeled somatostatin analogues demonstrates significant SSTR expression.

摘要

由于晚期髓样甲状腺癌和非碘亲和性分化型（非髓样）甲状腺癌的治疗选择有限且伴有显著毒性，因此靶向生长抑素受体（SSTRs）进行内放射治疗提供了一个有前景的选择。使用放射性标记生长抑素类似物的诊疗（治疗与诊断）已被证明是SSTR表达肿瘤管理中的一个里程碑。对于那些经（68）Ga标记生长抑素类似物的PET/CT显示有显著SSTR表达的患者，使用（177）Lu标记或（90）Y标记生长抑素类似物的肽受体放射性核素治疗在髓样和非髓样甲状腺癌的管理中可能发挥重要作用。